Company intelligence
KKH Advisors
Healthcare Strategic Communications
About KKH Advisors
KKH Advisors is a leading strategic communications firm specializing in biotech, healthcare, and life sciences. Known for navigating high-stakes moments — from company launches and funding milestones to clinical data, regulatory approvals, and IPOs — KKH Advisors helps innovators shape narratives that drive business outcomes. With deep expertise across biotech, medtech, and digital health, KKH partners with visionary leaders, from early-stage startups to public companies, to elevate their brands, build trust, and engage the audiences that matter most — including investors, media, partners, and patients. Founded in 2017, KKH Advisors has earned a reputation for hands-on counsel, strong relationships with top-tier and trade media, and a proven track record of helping companies grow, lead, and win in competitive markets.
Verified activity
Signals from KKH Advisors
4 published signals
Presence & Recognition
KKH Advisors was featured in Barron's
Reported by Kimberly Ha
Capital & Finance
KKH Advisors reported that Roivant Sciences and Pharvaris hit record highs on blowout and bull case results for lung and swelling disease treatments.
Reported by Kimberly Ha
Research & Knowledge
KKH Advisors reported that Roivant's pulmonary hypertension drug candidate mosliciguat reduced pulmonary vascular resistance in a Phase 2 trial surpassing analysts' expectations.
Reported by Kimberly Ha
Legal & Regulatory
KKH Advisors notes that RiboX Therapeutics has received U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for RXRG001 for the treatment of radiation-induced xerostomia and hyposalivation.
Reported by Kimberly Ha